An Investigational Drug Study With Suberoylanilide Hydroxamic Acid in Relapsed Diffuse Large B-cell Lymphoma (0683-013)

Inclusion Criteria: * Patient must be 18 years or older with relapsed Diffuse Large B-cell Lymphoma (DLBCL). * Stable disease or better for at least 3 months on most recent treatment * Have not received any chemotherapy, radiation therapy, major surgery, or any other investigational therapy for at least 4 weeks prior to entry in this study * Adequate blood testing, liver, and kidney function as required by the study. * Eligible subjects will allow tissue samples to be examined and stored. Exclusion Criteria: * Patient has been treated with other investigational agents with a similar anti-tumor mechanism. * Patient should not have failed more than 3 prior treatment regimens.